Slide 1: Issuer Free Writing Prospectus legend
The issuer, Urologix, Inc., has filed with the Securities and Exchange Commission (the “SEC”) a registration statement, including a preliminary prospectus (the "Preliminary Prospectus"), for the offering to which this communication relates. Delivery of this communication has been preceded by, or is
Slide 2: Company Overview June 2012
Company Overview June 2012
Slide 3: Disclaimer & Forward Looking Statements
Disclaimer & Forward Looking Statements This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that are not statements of historical fact may be
Slide 4: Follow-on Offering
Follow-on Offering Offering Size 5.2 million shares Over-allotment 15% Ticker ULGX Lockup 180 days (Directors and Officers) Use of Proceeds Fund sales and marketing initiatives, satisfy payments related to the Prostiva license agreement, fund research and development activities, as well as working c
Slide 5: The "new" Urologix
The “ new ” Urologix Urologix is the leading provider of in-office solutions for the early and effective treatment of obstructive and symptomatic lower urinary tract conditions due to benign prostatic hyperplasia (BPH). Cooled ThermoTherapy ™ (CTT) PROSTIVA ™ RF Therapy
Slide 6: Investment Highlights
Investment Highlights Over 8.7 million men in US diagnosed with BPH Positive demographics for growth Growing awareness of the limited effectiveness and significant side effects of BPH drugs Leading in-office solutions Combined products address larger patient population and expands base of existing U
Slide 7: Benign Prostatic Hyperplasia - BPH
Benign Prostatic Hyperplasia - BPH BPH is the most frequently diagnosed urological problem in aging men What is BPH? Non-cancerous prostate growth Progressive condition, associated with age When untreated or ineffectively treated with drugs, obstructive BPH can lead to serious conditions, including:
Slide 8: Market Opportunity
Market Opportunity Urologix’s Target Market *Source: Procedure estimates for CY2010 based on most recent CMS Part B CPT Code Utilization
Slide 9: Cooled ThermoTherapy
Cooled ThermoTherapy ™ CoolWave ® Control Unit CTC Advance ® Microwave Catheter Symmetrical heating pattern Relieves obstruction without causing damage to the urethra Urethra preserved with coolant circulated through catheter
Slide 10: PROSTIVA RF Therapy
PROSTIVA ™ RF Therapy Source: PROSTIVA TM RF Therapy System User Guide, Medtronic Inc. (May, 2010) Performed under direct visualization Relieves obstruction without causing damage to the urethra Needle ablation delivers radio frequency energy to create a focal lesion Able to precisely target specifi
Slide 11: Urologix Expands Addressable Population
Urologix Expands Addressable Population Vast majority of BPH patients treatable in-office* *Assumes patients are otherwise appropriate candidates based o n other inclusion and exclusion criteria contained in the labeling
Slide 12: BPH: Assessment of Clinical Outcomes
BPH: Assessment of Clinical Outcomes Symptomatic BPH measured by subjective scoring systems AUA Symptom Score (AUASS) is a 0-35 point scale, higher is more severe Outcomes measured in symptom score improvement * Barry MJ, et al, Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tra
Slide 13: Urologix's Outcomes are Durable
Urologix’s Outcomes are Durable Mynderse LA, Roehrborn CG, Partin AW, Preminger GM, Coté EP. Results of a 5-year Multicenter Trial of a New Generation Cooled High Energy Transurethral Microwave Thermal Therapy Catheter for Benign Prostatic Hyperplasia. Journal of Urology. 2011 May;185(5):1804-10 Coo
Slide 14: Multiple Drivers of Growth
Multiple Drivers of Growth Favorable market dynamics Growing awareness of BPH drug shortcomings Transformation of in-office competitive landscape Expanded market share & sales coverage Significant growth in installed base with Prostiva Cross-sell to increase urologists using both technologies Increa
Slide 15: BPH Drugs – Sentiment Changing
BPH Drugs – Sentiment Changing Past Present BPH drugs are new technology Large DTC effort drives awareness BPH drugs seen as efficacious, side effects minimized Available from any physician Patients perceive drugs as easy Drugs widely prescribed but >50% of patients have minimal clinical improvement
Slide 16: In-Office Therapy - Sentiment Changing
In-Office Therapy - Sentiment Changing Past Present Four major competitors battling for market share Urologists are confused with competitor comfort, cost and durability claims Urologists hear mixed messages from different companies With Prostiva, Urologix is clear leader of in-office market Improve
Slide 17: Sales and Marketing
Sales and Marketing Urologix’s sales and distribution team is comprised of: 22 quota-based direct sales reps 12 application specialists (mobile sales) 3 EU distributors (France, Italy, Sweden) Urologix customers (CTT + Prostiva) represent only 27% of the estimated 3,000 urology practices in the U.S.
Slide 18: Market Development "Think Outside the Pillbox" Campaign
Market Development “Think Outside the Pillbox” Campaign 20% (+) YOY revenue growth in initial targeted accounts Partner with urologists for targeted patient outreach Increase urologists’ awareness of patients’ dissatisfaction with Rx therapy Raise patient awareness of Urologix’s in- office options L
Slide 19: Experienced Management Team
Experienced Management Team Name Title Years of Healthcare Experience Stryker Warren, Jr. Chief Executive Officer Greg Fluet EVP & Chief Operating Officer Lisa Ackermann EVP, Sales & Marketing Brian Smrdel Chief Financial Officer
Slide 20: Financial Overview Q3 FY12
Financial Overview Q3 FY11 3/31/11 Q3 FY12 3/31/12 9 Mo. FY11 9 Mo. FY12 Source: SEC filings and Company reports (US$, thousands) Revenue $ 2,982 $ 4,735 $ 9,655 $ 12,530 Growth Rate 59% 30% Gross Margin % 54.1% 50.7% 54.8% 48.7% Operating Expense 2,598 3,241 7,699 * 9,164 Operating Income (Loss) (9
Slide 21: Financial Overview FY10-FY12 Guidance
Financial Overview FY10 6/30/10 FY11 6/30/11 FY12 Guidance Source: SEC filings and Company reports (US$, thousands) Revenue $ 14,771 $ 12,571 $17,000 - $17,500 Gross Margin % 55.5% 52.0% Operating Expense 10,459 10,267 Operating Income (Loss) (2,257) (3,726) Net Income (Loss) (2,169) (3,733)
Slide 22: Balance Sheet Summary
Balance Sheet Summary FY11 (6/30/11) Q3 FY12 (3/31/12)* (US$, thousands) Cash & Equivalents $ 3,061 $ 1,857 Current Assets 5,795 6,187 Other Assets 6,855 Total Assets 6,763 13,042 Current Liabilities 1,757 6,478 Other Liabilities 4,812 Equity 4,846 1,752 Total Liab. & Equity 6,763 13,042 * Includes
Slide 23: Investment Highlights
Investment Highlights “New” Urologix Large underpenetrated market Market dynamics favor in-office therapies Leading in-office solutions Early success of market development campaign Experienced management team driven to succeed
Slide 24: Contacts
Stryker Warren, Jr. Chief Executive Officer 763.475.7605 swarren@urologix.com Brian Smrdel Chief Financial Officer 763.475.7696 bsmrdel@urologix.com Contacts: Greg Fluet EVP & Chief Operating Officer 763.475.7690 gfluet@urologix.com